[kml_flashembed publishmethod=”static” fversion=”8.0.0″ useexpressinstall=”true” movie=”http://biogames.ee.ucla.edu/MalariaTraining.swf” width=”920″ height=”1300″ targetclass=”flashmovie”]
[/kml_flashembed]
[kml_flashembed publishmethod=”static” fversion=”8.0.0″ useexpressinstall=”true” movie=”http://biogames.ee.ucla.edu/MalariaTraining.swf” width=”920″ height=”1300″ targetclass=”flashmovie”]
[/kml_flashembed]
“Sustain Gains, Save Lives: Invest in Malaria.”
World Malaria Day was established in May 2007 by the 60th session of the World Health Assembly, the decision-making body of the World Health Organization (WHO). The day was established to provide education and understanding of malaria and disseminate information on malaria-control strategies, including community-based activities for malaria prevention and treatment in endemic areas.
According to the World Health Organization, approximately half the world’s population is at risk from malaria. And while malaria is a preventable and treatable disease, it still claims the life of a child every minute, with more than 90% of all malaria deaths occurring in Africa. [Read more…]
Many visitors to Malaria.com have traveled to malarial areas, so we are asking for your help. Malaria.com is conducting a survey of site visitors to compile valuable information about widely-used malaria prophylactics. We would like to hear about your experience with taking preventative medication against malaria. What drugs have you tried for malaria prevention? Have you experienced any side effects, and if so, what type?
Please click on the NEXT button below in order to help us learn more about malaria drugs and their possible side effects. [wpsqt name=” ” type=”survey”]
Imagine an insect repellent that not only is thousands of times more effective than DEET – the active ingredient in most commercial mosquito repellents – but also works against all types of insects, including flies, moths and ants.
That possibility has been created by the discovery of a new class of insect repellent made in the laboratory of Vanderbilt Professor of Biological Sciences and Pharmacology Laurence Zwiebel and reported this week in the online Early Edition of the Proceedings of the National Academy of Sciences.
“It wasn’t something we set out to find,” said David Rinker, a graduate student who performed the study in collaboration with graduate student Gregory Pask and post-doctoral fellow Patrick Jones. “It was an anomaly that we noticed in our tests.”
The tests were conducted as part of a major interdisciplinary research project to develop new ways to control the spread of malaria by disrupting a mosquito’s sense of smell supported by the Grand Challenges in Global Health Initiative funded by the Foundation for the NIH through a grant from the Bill & Melinda Gates Foundation.
“It’s too soon to determine whether this specific compound can act as the basis of a commercial product,” Zwiebel cautioned. “But it is the first of its kind and, as such, can be used to develop other similar compounds that have characteristics appropriate for commercialization.”
The discovery of this new class of repellent is based on insights that scientists have gained about the basic nature of the insect’s sense of smell in the last few years. Although the mosquito’s olfactory system is housed in its antennae, 10 years ago biologists thought that it worked in the same way at the molecular level as it does in mammals. A family of special proteins called odorant receptors, or ORs, sits on the surface of nerve cells in the nose of mammals and in the antennae of mosquitoes. When these receptors come into contact with smelly molecules, they trigger the nerves signaling the detection of specific odors.
In the last few years, however, scientists have been surprised to learn that the olfactory system of mosquitoes and other insects is fundamentally different. In the insect system, conventional ORs do not act autonomously. Instead, they form a complex with a unique co-receptor (called Orco) that is also required to detect odorant molecules. ORs are spread all over the antennae and each responds to a different odor. To function, however, each OR must be connected to an Orco.
“Think of an OR as a microphone that can detect a single frequency,” Zwiebel said. “On her antenna the mosquito has dozens of types of these microphones, each tuned to a specific frequency. Orco acts as the switch in each microphone that tells the brain when there is a signal. When a mosquito smells an odor, the microphone tuned to that smell will turn “on” its Orco switch. The other microphones remain off. However, by stimulating Orco directly we can turn them all on at once. This would effectively overload the mosquito’s sense of smell and shut down her ability to find blood.”
Because the researchers couldn’t predict what chemicals might modulate OR-Orco complexes, they decided to “throw the kitchen sink” at the problem. Through their affiliation with Vanderbilt’s Institute of Chemical Biology, they gained access to Vanderbilt’s high throughput screening facility, a technology intended for the drug discovery process, not for the screening of insect ORs.
Jones used genetic engineering techniques to insert mosquito odorant receptors into the human embryonic kidney cells used in the screening process. Rinker tested these cells against a commercial library of 118,000 small molecules normally used in drug development. They expected to find, and did find, a number of compounds that triggered a response in the conventional mosquito ORs they were screening, but they were surprised to find one compound that consistently triggered OR-Orco complexes, leading them to conclude that they had discovered the first molecule that directly stimulates the Orco co-receptor. They have named the compound VUAA1.
Although it is not an odorant molecule, the researchers determined that VUAA1 activates insect OR-Orco complexes in a manner similar to a typical odorant molecule. Jones also verified that mosquitoes respond to exposure to VUAA1, a crucial step in demonstrating that VUAA1 can affect a mosquito’s behavior.
“If a compound like VUAA1 can activate every mosquito OR at once, then it could overwhelm the insect’s sense of smell, creating a repellent effect akin to stepping onto an elevator with someone wearing too much perfume, except this would be far worse for the mosquito,” Jones said.
The researchers have just begun behavioral studies with the compound. In preliminary tests with mosquitoes, they have found that VUAA1 is thousands of times more effective than DEET.
They have also established that the compound stimulates the OR-Orco complexes of flies, moths and ants. As a result, “VUAA1 opens the door for the development of an entirely new class of agents, which could be used not only to disrupt disease vectors, but also the nuisance insects in your backyard or the agricultural pests in your crops,” Jones said.
Many questions must be answered before VUAA1 can be considered for commercial applications. Zwiebel’s team is currently working with researchers in Vanderbilt’s Drug Discovery Program to pare away the parts of VUAA1 that don’t contribute to its activity. Once that is done, they will begin testing its toxicity.
Vanderbilt University has filed for a patent on this class of compounds and is talking with potential corporate licensees interested in incorporating them into commercial products, with special focus on development of products to reduce the spread of malaria in the developing world.
Source: Proceedings of the National Academy of Sciences, Vanderbilt University
NetGuarantee, a new innovative finance facility, announces its first transaction with Zurich in North America, part of the Zurich Financial Services Group, to celebrate World Malaria Day today, April 25. This collaboration will help accelerate access to and advance the delivery of vital malaria prevention tools in Africa by six to 10 months, and shows how core business competencies and best practices can improve efficiencies in global health and save lives.
The Times wrote: “A few nonprofit groups have recently announced plans to wind down, not over financial problems but because their missions are nearly finished. Most notable, perhaps, is Malaria No More, a popular nonprofit that supplies bed nets in malaria zones. Its goal is to end deaths from malaria, a target it sees fast approaching. The charity has announced plans to close in 2015, but it is keeping its options open in the unlikely event that advances against malaria are reversed.”
The New York Times story features an image of Scott Case, vice chairman of Malaria No More, with a caption indicating the organization will close in 2015.
Just two days later on April 3, Malaria No More released a statement, reprinted in its entirety below, refuting the Times story:
——–
Yesterday an article appeared in the New York Times, entitled “Mission Accomplished, Nonprofits Go Out of Business”. This article has caused significant concerns and confusion, both for Malaria No More and our partners.
The premise of the article—that mission-driven nonprofits work to reach their goals and consequently shut their doors—is a good one. By focusing tirelessly on the goal, organizations drive for sustainable change and progress. Yet premature declarations of victory risk putting both the progress and the goal in jeopardy.
The entire malaria community should be incredibly proud of the progress we’ve made. We look forward to the day when no one is dying from malaria—but we know that there is a lot of work to do until then.
Join the discussion in the Malaria.com Group: Bed Nets Discussion.
——–
Sources: NYTimes; Malaria No More
In Benin, Catherine Degboesse and her newborn baby receive a free insecticide-treated mosquito net from Simon Kpossa (left), a member of the Ministry of Health's net distribution team. Source: André Roussel, USAID/Benin
The President’s Malaria Initiative (PMI)
Benin is one of the 15 original countries benefiting from PMI, which was launched in 2005 and is led by the U.S. Agency for International Development and implemented together with the Centers for Disease Control and Prevention.
[Read more…]